Related Experiment Video
Updated: Mar 8, 2026
07:14
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
Published on: July 11, 2025
607
New developments in anti-malarial target candidate and product profiles.
Jeremy N Burrows1, Stephan Duparc1, Winston E Gutteridge2
1Medicines for Malaria Venture, Route de Pré Bois 20, 1215, Geneva 15, Switzerland.
Malaria Journal
|January 15, 2017
Summary
New anti-malarial drugs are advancing, addressing drug resistance and simplifying treatment. Research now targets long-acting, safe medicines for vulnerable groups to achieve malaria eradication.
Area of Science:
- * Malariology and Tropical Medicine
- * Pharmaceutical Development and Drug Discovery
Background:
- * A decade of progress in anti-malarial drug discovery has intensified efforts towards malaria elimination and eradication.
- * Significant increases in the number and diversity of novel anti-malarial molecules are in pre-clinical and early clinical development.
- * Key challenges include multi-drug resistant malaria strains and the need for simplified treatment regimens.
Purpose of the Study:
- * To review changes in anti-malarial drug target candidate and target product profiles over the past four years.
- * To identify gaps in the current malaria treatment and prevention armamentarium.
- * To highlight the evolving understanding of challenges in developing next-generation anti-malarial medicines.
Main Methods:
- * Literature review and analysis of recent trends in anti-malarial drug development.
- * Examination of target candidate and target product profiles for new anti-malarial medicines.
- * Identification of critical unmet needs in malaria control and eradication strategies.
Main Results:
- * Increased focus on developing new medicines for disease treatment, transmission prevention, and chemoprotection (including long-acting and parenteral formulations).
- * Identification of critical needs for drugs to treat severe malaria and endectocides.
- * Recognition of the necessity for safe and well-tolerated medicines for vulnerable populations (pregnant women, malnourished individuals, co-infected patients).
Conclusions:
- * The field of anti-malarial drug development is maturing, with a clearer understanding of the challenges for future progress.
- * Continued innovation is essential to produce safe, effective, and accessible medicines for malaria control, elimination, and eventual eradication.
- * Addressing drug resistance and ensuring suitability for vulnerable groups are paramount for global malaria eradication efforts.
Keywords:
Elimination drug discoveryEradication drug discoveryMalariaMedicinesPlasmodiumTarget candidate profileTarget product profileMore Related Videos
05:28Standard Membrane Feeding Assay for the Detection of Plasmodium falciparum Infection in Anopheles Mosquito Vectors
Published on: May 12, 2022
3.8K
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.9K
Related Concept Videos
01:31ABC Transporters: Exporter
6.9K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
6.9K
01:26Targets for Drug Action: Overview
10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K
01:29Pharmacogenomics: Identification of New Drug Targets
57
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
57
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
261
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
261
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
77
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
77